Abdi İbrahim İlaç Sanayi ve Ticaret AŞ 2018 SR
The report outlines Abdi Ibrahim's sustainability performance and achievements for the 2017-2018 period. The company maintained its leadership in the Turkish pharmaceutical industry, increasing its domestic market share to 6.6% in 2018. Key developments included the inauguration of AbdiBio, Turkey's largest biotechnological production facility, and the launch of the HBVizyon project to combat Hepatitis B. Abdi Ibrahim also demonstrated its commitment to diversity, with women representing 52% of head office employees and 68% of R&D center staff. Additionally, the company implemented various environmental initiatives, resulting in significant energy and water savings.
Company: Abdi İbrahim İlaç Sanayi ve Ticaret AŞ
Country: Turkey
Year: 2018
Type: SR
Pages: 118
Abdi İbrahim İlaç Sanayi ve Ticaret AŞ
The report outlines Abdi Ibrahim's sustainability performance and achievements for the 2017-2018 period. The company maintained its leadership in the Turkish pharmaceutical industry, increasing its domestic market share to 6.6% in 2018. Key developments included the inauguration of AbdiBio, Turkey's largest biotechnological production facility, and the launch of the HBVizyon project to combat Hepatitis B. Abdi Ibrahim also demonstrated its commitment to diversity, with women representing 52% of head office employees and 68% of R&D center staff. Additionally, the company implemented various environmental initiatives, resulting in significant energy and water savings.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2017 - Dec 31, 2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Renewable Energy
Water Consumption
Women in Management
Workplace Fatalities
Employees